Consequences of chronic kidney disease (CKD) in older people

Phase 4

Completed

• Conditions: Topic: Renal and Urogenital; Subtopic: Renal and Urogenital (all Subtopics); Disease: Renal; Urological and Genital Diseases; Chronic kidney disease

• Registration Number: ISRCTN84743489
• Lead Sponsor: Derby Hospital NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2010-02-08
• Study Start: 2010-05-19
• Last Update Posted: 6 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Aged greater than 70 years
2. CKD 3, 4 or hypertensive (greater than 130/80) with no renal disease

Exclusion Criteria

1. Use of more than 3 drugs for blood pressure control
2. Likely to develop CKD 5 within one year
3. Poor mobility precluding completion of assessment
4. Diabetes
5. Abbreviated mental test (AMT) score < 8
6. Recent acute illness (within 3 months)
7. Ischaemic heart disease requiring beta-blockade (nitrates/nicorandil are permitted)
8. Involvement in another clinical trial within 3 months
9. Attending day hospital or attending falls reduction services
10. Residents in nursing or residential homes
11. Renovascular disease precluding ACE-inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) usage
12. BP prior to antihypertensive withdrawal > 160/90mmHg
13. Malignant hypertension
14. Severe peripheral vascular disease or significant valvular heart disease
15. Heart failure (NYHA III/IV) or other cause to prevent diuretic withdrawal
16. Atrial fibrillation or other significant arrhythmia (precludes pulse wave velocity (PWV) measurement)
17. Currently taking antihypertensive medication for which MRHA approval (CTA) has not been granted
18. Active Obstructive uropathy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in Baroreflex sensitivity (a composite marker of autonomic function) in response to antihypertensive therapy, assessed at each assessment

Secondary Outcome Measures

Name	Time	Method
<br> Assessed at each assessment:<br> 1. Cardiovascular predictors of Falls propensity<br> 2. Cardiovascular consequences of antihypertensive therapy<br>